The vaccine developer's series C-plus round was co-led by SoftBank Vision Fund and came just three months after it closed a $700m series C.

China-based mRNA vaccine developer Suzhou Abogen Biosciences has received up to $300m in a series C-plus round co-led by internet and telecommunications group SoftBank’s Vision Fund, DealStreetAsia reported today, citing a company statement.

Venture capital firm 5Y Capital co-led the round, which included real estate developer Royal Group’s Chimera Abu Dhabi subsidiary, financial services group Mirae Asset, IMO Ventures, Fortune Ocean and Jinyi Capital.

Abogen has created an messenger RNA technology platform it uses to develop vaccines, and will put…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn